JAMA Oncology : Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.

Related Content:

• Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib